NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NON-ALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NON-ALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against fatty liver disease in early trial
Disease control CompletedThis study tested an experimental drug called HSK31679 in 186 Chinese adults with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease with scarring. Participants took either 80 mg, 160 mg, or a placebo daily for 52 weeks. The main goal was to see if the drug could…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 11:20 UTC
-
Promising new drug shows hope for fatty liver disease
Disease control CompletedThis study tested a new drug called pemvidutide in 212 adults with NASH, a serious fatty liver disease that can lead to liver damage. The goal was to see if the drug could reduce liver fat and scarring without making the disease worse. Participants received either the drug or a p…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New drug shows promise for fatty liver in early trial
Disease control CompletedThis study tested a drug called TRO19622 in 22 adults with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants took either the drug or a placebo for one month to see if it safely lowered liver enzymes. The goal was to check short-term safety and effe…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New drug shows promise against fatty liver and obesity in Late-Stage trial
Disease control CompletedThis study tested a medicine called survodutide in 218 adults with overweight or obesity and a liver condition called NASH (fatty liver with inflammation). Participants received weekly injections of survodutide or a placebo for about a year, along with diet and exercise advice. T…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
First human trial of AZD4076 checks safety in healthy men
Knowledge-focused CompletedThis study tested a new drug called AZD4076 in 40 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. Since this was the first time the drug was given to humans, the main …
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 17, 2026 11:20 UTC